Abstract
Hepatitis E virus (HEV) infections are a major cause of acute viral hepatitis in humans worldwide. In immunocompetent individuals, the majority of HEV infections remain asymptomatic and lead to spontaneous clearance of the virus, and only a minority of individuals with infection (5–16%) experience symptoms of acute viral hepatitis. However, HEV infections can cause up to 30% mortality in pregnant women, become chronic in immunocompromised patients and cause extrahepatic manifestations. A growing body of evidence suggests that the host immune response to infection with different HEV genotypes is a critical determinant of distinct HEV infection outcomes. In this Review, we summarize key components of the innate and adaptive immune responses to HEV, including the underlying immunological mechanisms of HEV associated with acute and chronic liver failure and interactions between T cell and B cell responses. In addition, we discuss the current status of vaccines against HEV and raise outstanding questions regarding the immune responses induced by HEV and treatment of the disease, highlighting areas for future investigation.
Key points
-
The severity of hepatitis E virus (HEV) infection varies: for example, it is self-limiting in most immunocompetent individuals but can be fatal in pregnant women and lead to chronicity in immunocompromised individuals.
-
A growing body of evidence suggests that the host immune response to infection with different HEV genotypes is a critical determinant of the distinct outcomes of HEV infection.
-
HEV has developed strategies to evade and disrupt innate immune signalling by antagonizing interferon induction and signalling.
-
T cell immunity is of paramount importance in the resolution of HEV infections.
-
B cell immunity and antibody responses can provide sterilizing immunity and long-lasting protection against HEV re-infection.
-
Active and passive immunization seem to effectively prevent severe acute hepatitis E in most cases.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rein, D. B., Stevens, G. A., Theaker, J., Wittenborn, J. S. & Wiersma, S. T. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 55, 988–997 (2012).
World Health Organization. Hepatitis E: Fact Sheet https://www.who.int/news-room/fact-sheets/detail/hepatitis-e (2021).
Li, P. et al. The global epidemiology of hepatitis E virus infection: a systematic review and meta-analysis. Liver Int. 40, 1516–1528 (2020).
Khuroo, M. S. Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type. Am. J. Med. 68, 818–824 (1980).
Smith, D. B. et al. Update: proposed reference sequences for subtypes of hepatitis E virus (species Orthohepevirus A). J. Gen. Virol. 101, 692–698 (2020).
Nimgaonkar, I., Ding, Q., Schwartz, R. E. & Ploss, A. Hepatitis E virus: advances and challenges. Nat. Rev. Gastroenterol. Hepatol. 15, 96–110 (2018).
Gouttenoire, J. et al. Palmitoylation mediates membrane association of hepatitis E virus ORF3 protein and is required for infectious particle secretion. PLoS Pathog. 14, e1007471 (2018).
Hartl, J., Wehmeyer, M. H. & Pischke, S. Acute hepatitis E: two sides of the same coin. Viruses 8, 299 (2016).
Navaneethan, U., Al Mohajer, M. & Shata, M. T. Hepatitis E and pregnancy: understanding the pathogenesis. Liver Int. 28, 1190–1199 (2008).
Kinast, V., Klöhn, M., Nocke, M. K., Todt, D. & Steinmann, E. Hepatitis E virus species barriers: seeking viral and host determinants. Curr. Opin. Virol. 56, 101274 (2022).
Chauhan, A. et al. Hepatitis E virus transmission to a volunteer. Lancet 341, 149–150 (1993).
European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis E virus infection. J. Hepatol. 68, 1256–1271 (2018).
Huang, S.-J., Liu, X.-H., Zhang, J. & Ng, M.-H. Protective immunity against HEV. Curr. Opin. Virol. 5, 1–6 (2014).
Balayan, M. S. et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology 20, 23–31 (1983). Identification of hepatitis E virus as a previously unknown non-A, non-B virus species, by immune electron microscopy.
Walker, C. M. Adaptive immune responses in hepatitis A virus and hepatitis E virus infections.Cold Spring Harb. Perspect. Med. 9, a033472 (2019).
Todt, D. et al. Robust hepatitis E virus infection and transcriptional response in human hepatocytes. Proc. Natl Acad. Sci. USA 117, 1731–1741 (2020).
Krain, L. J., Nelson, K. E. & Labrique, A. B. Host immune status and response to hepatitis E virus infection. Clin. Microbiol. Rev. 27, 139–165 (2014).
Kamar, N. et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N. Engl. J. Med. 358, 811–817 (2008). First description of chronic hepatitis E virus infection in organ-transplant recipients.
Abravanel, F. et al. Conventional and innate lymphocytes response at the acute phase of HEV infection in transplanted patients. J. Infect. 72, 723–730 (2016).
Kamar, N. & Pischke, S. Acute and persistent hepatitis E virus genotype 3 and 4 infection: clinical features, pathogenesis, and treatment.Cold Spring Harb. Perspect. Med. 9, a031872 (2019).
Gotlieb, N., Moradpour, D. & Shouval, D. Hepatitis A and E — differences and commonalities. J. Hepatol. 72, 578–580 (2020).
Das, A. et al. Cell entry and release of quasi-enveloped human hepatitis viruses. Nat. Rev. Microbiol. 21, 573–589 (2023).
von Felden, J. et al. The burden of hepatitis E among patients with haematological malignancies: a retrospective European cohort study. J. Hepatol. 71, 465–472 (2019).
Dalton, H. R., Bendall, R. P., Keane, F. E., Tedder, R. S. & Ijaz, S. Persistent carriage of hepatitis E virus in patients with HIV infection. N. Engl. J. Med. 361, 1025–1027 (2009).
Dalton, H. R. et al. Hepatitis E virus and neurological injury. Nat. Rev. Neurol. 12, 77–85 (2016).
Kamar, N., Marion, O., Abravanel, F., Izopet, J. & Dalton, H. R. Extrahepatic manifestations of hepatitis E virus. Liver Int. 36, 467–472 (2016).
Kinast, V., Burkard, T. L., Todt, D. & Steinmann, E. Hepatitis E virus drug development. Viruses 11, 485 (2019).
Debing, Y. et al. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. Gastroenterology 147, 1008–11.e7 (2014).
Gömer, A. et al. Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients. Hepatology. 78, 1882–1895 (2023).
Todt, D. et al. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut 65, 1733–1743 (2016).
Aggarwal, R. & Jameel, S. Hepatitis E. Hepatology 54, 2218–2226 (2011).
Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783–801 (2006).
Feng, Z. & Lemon, S. M. Innate immunity to enteric hepatitis viruses.Cold Spring Harb. Perspect. Med. 9, a033464 (2019).
Thompson, M. R., Kaminski, J. J., Kurt-Jones, E. A. & Fitzgerald, K. A. Pattern recognition receptors and the innate immune response to viral infection. Viruses 3, 920–940 (2011).
Li, K., Chen, Z., Kato, N., Gale, M. & Lemon, S. M. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-β production in hepatocytes. J. Biol. Chem. 280, 16739–16747 (2005).
Devhare, P. B., Chatterjee, S. N., Arankalle, V. A. & Lole, K. S. Analysis of antiviral response in human epithelial cells infected with hepatitis E virus. PLoS One 8, e63793 (2013).
Choi, Y. H., Zhang, X., Tran, C. & Skinner, B. Expression profiles of host immune response-related genes against HEV genotype 3 and genotype 1 infections in rhesus macaques. J. Viral Hepat. 25, 986–995 (2018).
Lee, M. S. & Kim, Y.-J. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu. Rev. Biochem. 76, 447–480 (2007).
Devhare, P. B., Desai, S. & Lole, K. S. Innate immune responses in human hepatocyte-derived cell lines alter genotype 1 hepatitis E virus replication efficiencies. Sci. Rep. 6, 26827 (2016).
Majumdar, M., Ratho, R. K., Chawla, Y. & Singh, M. P. Role of TLR gene expression and cytokine profiling in the immunopathogenesis of viral hepatitis E. J. Clin. Virol. 73, 8–13 (2015).
Sehgal, R. et al. Impaired monocyte-macrophage functions and defective Toll-like receptor signaling in hepatitis E virus-infected pregnant women with acute liver failure. Hepatology 62, 1683–1696 (2015).
Arya, R. P., Mishra, N., Biswas, K. & Arankalle, V. A. Association of Toll-like receptor 4 polymorphism with hepatitis E virus-infected Indian patients. J. Viral Hepat. 25, 1617–1623 (2018).
Xu, L. et al. RIG-I is a key antiviral interferon-stimulated gene against hepatitis E virus regardless of interferon production. Hepatology 65, 1823–1839 (2017).
Li, Y. et al. MDA5 against enteric viruses through induction of interferon-like response partially via the JAK-STAT cascade. Antivir. Res. 176, 104743 (2020).
Wang, W. et al. The RNA genome of hepatitis E virus robustly triggers an antiviral interferon response. Hepatology 67, 2096–2112 (2018).
Yin, X. et al. Hepatitis E virus persists in the presence of a type III interferon response. PLoS Pathog. 13, e1006417 (2017).
Rehwinkel, J. & Gack, M. U. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat. Rev. Immunol. 20, 537–551 (2020).
Sooryanarain, H., Heffron, C. L. & Meng, X.-J. The U-rich untranslated region of the hepatitis E virus induces differential type I and type III interferon responses in a host cell-dependent manner. mBio 11, e03103-19 (2020).
Uzri, D. & Gehrke, L. Nucleotide sequences and modifications that determine RIG-I/RNA binding and signaling activities. J. Virol. 83, 4174–4184 (2009).
Saito, T., Owen, D. M., Jiang, F., Marcotrigiano, J. & Gale, M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454, 523–527 (2008).
Lhomme, S. et al. Hepatitis E virus: how it escapes host innate immunity. Vaccines 8, 422 (2020).
Sayed, I. M. et al. Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. Gut 66, 920–929 (2017).
Yu, C. et al. Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees: similarities and differences. J. Virol. 84, 11264–11278 (2010).
Moal, V. et al. Chronic hepatitis E virus infection is specifically associated with an interferon-related transcriptional program. J. Infect. Dis. 207, 125–132 (2013).
Wu, X. et al. Pan-genotype hepatitis E virus replication in stem cell-derived hepatocellular systems. Gastroenterology 154, 663–674.e7 (2018).
Marion, O. et al. Hepatitis E virus replication in human intestinal cells. Gut 69, 901–910 (2020).
Murata, K. et al. IFN-λ3 as a host immune response in acute hepatitis E virus infection. Cytokine 125, 154816 (2020).
Gouilly, J. et al. Genotype specific pathogenicity of hepatitis E virus at the human maternal-fetal interface. Nat. Commun. 9, 4748 (2018).
Purcell, R. H. et al. Pathobiology of hepatitis E: lessons learned from primate models. Emerg. Microbes Infect. 2, e9 (2013).
Allweiss, L. et al. Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation. J. Hepatol. 64, 1033–1040 (2016).
van de Garde, M. D. B. et al. Interferon-alpha treatment rapidly clears Hepatitis E virus infection in humanized mice. Sci. Rep. 7, 8267 (2017).
Knegendorf, L. et al. Hepatitis E virus replication and interferon responses in human placental cells. Hepatol. Commun. 2, 173–187 (2018).
Moal, V. et al. Hepatitis E virus serological testing in kidney transplant recipients with elevated liver enzymes in 2007-2011 in southeastern France. Diagn. Microbiol. Infect. Dis. 76, 116–118 (2013).
Schoggins, J. W. & Rice, C. M. Interferon-stimulated genes and their antiviral effector functions. Curr. Opin. Virol. 1, 519–525 (2011).
Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481–485 (2011).
Zhang, F. et al. Hepatitis E genotype 4 virus from feces of monkeys infected experimentally can be cultured in PLC/PRF/5 cells and upregulate host interferon-inducible genes. J. Med. Virol. 86, 1736–1744 (2014).
Sooryanarain, H. et al. ISG15 modulates type I interferon signaling and the antiviral response during hepatitis E virus replication. J. Virol. 91, e00621-17 (2017).
Xu, L. et al. IFN regulatory factor 1 restricts hepatitis E virus replication by activating STAT1 to induce antiviral IFN-stimulated genes. FASEB J. 30, 3352–3367 (2016).
Glitscher, M. et al. Identification of the interferon-inducible GTPase GBP1 as major restriction factor for the hepatitis E virus. J. Virol. 95, e01564-20 (2021).
Wang, M., Huang, Y., He, M., Peng, W.-J. & Tian, D.-Y. Effects of hepatitis E virus infection on interferon production via ISG15. World J. Gastroenterol. 24, 2173–2180 (2018).
Hermann, M. & Bogunovic, D. ISG15: in sickness and in health. Trends Immunol. 38, 79–93 (2017).
Daugherty, M. D. & Malik, H. S. Rules of engagement: molecular insights from host-virus arms races. Annu. Rev. Genet. 46, 677–700 (2012).
Hu, B., Huang, S. & Yin, L. The cytokine storm and COVID-19. J. Med. Virol. 93, 250–256 (2021).
Li, H., Huang, M.-H., Jiang, J.-D. & Peng, Z.-G. Hepatitis C: from inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy. World J. Gastroenterol. 24, 5297–5311 (2018).
Li, Y. et al. Hepatitis E virus infection activates NOD-like receptor family pyrin domain-containing 3 inflammasome antagonizing interferon response but therapeutically targetable. Hepatology 75, 196–212 (2022).
Debes, J. D., Groothuismink, Z. M. A., Doukas, M., de Man, R. A. & Boonstra, A. Immune dissociation during acute hepatitis E infection. Int. J. Infect. Dis. 87, 39–42 (2019).
Saravanabalaji, S. et al. Viral load, antibody titers and recombinant open reading frame 2 protein-induced TH1/TH2 cytokines and cellular immune responses in self-limiting and fulminant hepatitis E. Intervirology 52, 78–85 (2009).
Kumar, A. et al. Association of cytokines in hepatitis E with pregnancy outcome. Cytokine 65, 95–104 (2014).
Behrendt, P. et al. Exacerbation of hepatitis E virus infection during anti-TNFα treatment. Joint Bone Spine 84, 217–219 (2017).
Kinast, V. et al. Janus kinase-inhibition modulates hepatitis E virus infection. Antivir. Res. 217, 105690 (2023).
Mishra, N. & Arankalle, V. A. Association of polymorphisms in the promoter regions of TNF-α (-308) with susceptibility to hepatitis E virus and TNF-α (-1031) and IFN-γ (+874) genes with clinical outcome of hepatitis E infection in India. J. Hepatol. 55, 1227–1234 (2011).
Devi, S. G., Kumar, A., Kar, P., Husain, S. A. & Sharma, S. Association of pregnancy outcome with cytokine gene polymorphisms in HEV infection during pregnancy. J. Med. Virol. 86, 1366–1376 (2014).
Sung, P. S. et al. Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness. Proc. Natl Acad. Sci. USA 112, 10443–10448 (2015).
Shin, E.-C., Sung, P. S. & Park, S.-H. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat. Rev. Immunol. 16, 509–523 (2016).
Todt, D. et al. Antiviral activities of different interferon types and subtypes against hepatitis E virus replication. Antimicrob. Agents Chemother. 60, 2132–2139 (2016).
Zhou, X. et al. Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection. J. Viral Hepat. 23, 294–304 (2016).
Kamar, N. et al. Pegylated interferon-α for treating chronic hepatitis E virus infection after liver transplantation. Clin. Infect. Dis. 50, e30–e33 (2010).
Haagsma, E. B., Riezebos-Brilman, A., van den Berg, A. P., Porte, R. J. & Niesters, H. G. M. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transplant. 16, 474–477 (2010).
Sarasin-Filipowicz, M. et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl Acad. Sci. USA 105, 7034–7039 (2008).
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J. Hepatol. 73, 1170–1218 (2020).
Enomoto, N. et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J. Clin. Invest. 96, 224–230 (1995).
World Health Organization. Hepatitis C https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (2024).
Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399–401 (2009).
Prokunina-Olsson, L. et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45, 164–171 (2013).
Thomas, D. L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798–801 (2009).
Kamar, N. et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 140, 1481–1489 (2011).
Plosker, G. L. & Foster, R. H. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 59, 323–389 (2000).
Mejia, J. C., Basu, A. & Shapiro, R. In: Kidney Transplantation — Principles and Practice (eds Morris, P. J. & Knechtle, S. J.) 231–249 (Elsevier, 2014).
Wang, Y. et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology 146, 1775–1783 (2014).
Wang, Y., Metselaar, H. J., Peppelenbosch, M. P. & Pan, Q. Chronic hepatitis E in solid-organ transplantation: the key implications of immunosuppressants. Curr. Opin. Infect. Dis. 27, 303–308 (2014).
Nan, Y. et al. Hepatitis E virus inhibits type I interferon induction by ORF1 products. J. Virol. 88, 11924–11932 (2014).
Bagdassarian, E. et al. The amino-terminal region of hepatitis E virus ORF1 containing a methyltransferase (Met) and a papain-like cysteine protease (PCP) domain counteracts type I interferon response. Viruses 10, 726 (2018).
Kim, E. & Myoung, J. Hepatitis E virus papain-like cysteine protease inhibits type I interferon induction by down-regulating melanoma differentiation-associated gene 5. J. Microbiol. Biotechnol. 28, 1908–1915 (2018).
Kang, S. et al. Hepatitis E virus methyltransferase inhibits type I interferon induction by targeting RIG-I. J. Microbiol. Biotechnol. 28, 1554–1562 (2018).
Myoung, J., Lee, J. Y. & Min, K. S. Methyltransferase of a cell culture-adapted hepatitis E inhibits the MDA5 receptor signaling pathway. J. Microbiol. 57, 1126–1131 (2019).
Myoung, J. & Min, K. Dose-dependent inhibition of melanoma differentiation-associated gene 5-mediated activation of type I interferon responses by methyltransferase of hepatitis E virus. J. Microbiol. Biotechnol. 29, 1137–1143 (2019).
Dong, C. et al. Suppression of interferon-α signaling by hepatitis E virus. Hepatology 55, 1324–1332 (2012).
He, M. et al. The ORF3 protein of genotype 1 hepatitis E virus suppresses TLR3-induced NF-κB signaling via TRADD and RIP1. Sci. Rep. 6, 27597 (2016).
Lei, Q. et al. HEV ORF3 downregulates TLR7 to inhibit the generation of type I interferon via impairment of multiple signaling pathways. Sci. Rep. 8, 8585 (2018).
Lei, Q. et al. ORF3 of hepatitis E virus inhibits the expression of proinflammatory cytokines and chemotactic factors in LPS-stimulated human PMA-THP1 cells by inhibiting NF-κB pathway. Viral Immunol. 29, 105–111 (2016).
Sayed, I. M. et al. Replication of hepatitis E virus (HEV) in primary human-derived monocytes and macrophages in vitro. Vaccines 8, 239 (2020).
Surjit, M., Varshney, B. & Lal, S. K. The ORF2 glycoprotein of hepatitis E virus inhibits cellular NF-κB activity by blocking ubiquitination mediated proteasomal degradation of IκBα in human hepatoma cells. BMC Biochem. 13, 7 (2012).
Tian, Y. et al. Systematic identification of hepatitis E virus ORF2 interactome reveals that TMEM134 engages in ORF2-mediated NF-κB pathway. Virus Res. 228, 102–108 (2017).
Lin, S. et al. The capsid protein of hepatitis E virus inhibits interferon induction via its N-terminal arginine-rich motif. Viruses 11, 1050 (2019).
Hingane, S., Joshi, N., Surjit, M. & Ranjith-Kumar, C. T. Hepatitis E virus ORF2 inhibits RIG-I mediated interferon response. Front. Microbiol. 11, 656 (2020).
Meister, T. L., Bruening, J., Todt, D. & Steinmann, E. Cell culture systems for the study of hepatitis E virus. Antivir. Res. 163, 34–49 (2019).
LeDesma, R. et al. Structural features stabilized by divalent cation coordination within hepatitis E virus ORF1 are critical for viral replication. eLife 12, e80529 (2023).
Ju, C. & Tacke, F. Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. Cell. Mol. Immunol. 13, 316–327 (2016).
Martinon, F., Mayor, A. & Tschopp, J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27, 229–265 (2009).
Björkström, N. K., Strunz, B. & Ljunggren, H.-G. Natural killer cells in antiviral immunity. Nat. Rev. Immunol. 22, 112–123 (2022).
Caligiuri, M. A. Human natural killer cells. Blood 112, 461–469 (2008).
Rehermann, B. Natural killer cells in viral hepatitis. Cell. Mol. Gastroenterol. Hepatol. 1, 578–588 (2015).
Srivastava, R., Aggarwal, R., Bhagat, M. R., Chowdhury, A. & Naik, S. Alterations in natural killer cells and natural killer T cells during acute viral hepatitis E. J. Viral Hepat. 15, 910–916 (2008).
Das, R. & Tripathy, A. Increased expressions of NKp44, NKp46 on NK/NKT-like cells are associated with impaired cytolytic function in self-limiting hepatitis E infection. Med. Microbiol. Immunol. 203, 303–314 (2014).
Prabhu, S. B. et al. Study of cellular immune response against Hepatitis E virus (HEV). J. Viral Hepat. 18, 587–594 (2011).
Barragué, H. et al. Mobilization of γδ T cells and IL-10 production at the acute phase of hepatitis E virus infection in cytomegalovirus carriers. J. Immunol. 206, 1027–1038 (2021).
Vantourout, P. & Hayday, A. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat. Rev. Immunol. 13, 88–100 (2013).
Lunemann, S. et al. Compromised function of natural killer cells in acute and chronic viral hepatitis. J. Infect. Dis. 209, 1362–1373 (2014).
Khakoo, S. I. et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305, 872–874 (2004).
Alter, G. et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 476, 96–100 (2011).
Klenerman, P. & Thimme, R. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut 61, 1226–1234 (2012).
Hoogeveen, R. C. et al. Hepatitis B virus-specific CD4 T cell responses differentiate functional cure from chronic surface antigen+ infection. J. Hepatol. 77, 1276–1286 (2022).
Kumar, B. V., Connors, T. J. & Farber, D. L. Human T cell development, localization, and function throughout life. Immunity 48, 202–213 (2018).
Srivastava, R. et al. Cellular immune responses in acute hepatitis E virus infection to the viral open reading frame 2 protein. Viral Immunol. 20, 56–65 (2007).
Brown, A. et al. Characterization of the specificity, functionality, and durability of host T-cell responses against the full-length hepatitis E virus. Hepatology 64, 1934–1950 (2016).
Suneetha, P. V. et al. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology 55, 695–708 (2012). First association between chronic hepatitis E and impaired HEV-specific T cell responses and restoration of HEV-specific T cell responses through blockage of the PD1 or CTLA4 pathways.
Agrawal, V., Goel, A., Rawat, A., Naik, S. & Aggarwal, R. Histological and immunohistochemical features in fatal acute fulminant hepatitis E. Indian J. Pathol. Microbiol. 55, 22–27 (2012).
Husain, M. M., Aggarwal, R., Kumar, D., Jameel, S. & Naik, S. Effector T cells immune reactivity among patients with acute hepatitis E. J. Viral Hepat. 18, e603–e608 (2011).
Tripathy, A. S., Das, R., Rathod, S. B. & Arankalle, V. A. Cytokine profiles, CTL response and T cell frequencies in the peripheral blood of acute patients and individuals recovered from hepatitis E infection. PLoS One 7, e31822 (2012).
Gisa, A. et al. Cross-genotype-specific T-cell responses in acute hepatitis E virus (HEV) infection. J. Viral Hepat. 23, 305–315 (2016). This study described the discovery of cross-genotype T cell responses that might suggest a potential role in cross-genotype-specific protection between HEV genotypes 1 and 3.
El Costa, H. et al. Effector memory CD8 T cell response elicits hepatitis E virus genotype 3 pathogenesis in the elderly. PLoS Pathog. 17, e1009367 (2021).
Shata, M. T. et al. Characterization of hepatitis E-specific cell-mediated immune response using IFN-γ ELISPOT assay. J. Immunol. Methods 328, 152–161 (2007).
Wu, T. et al. Specific cellular immune response in hepatitis E patients. Intervirology 51, 322–327 (2008).
Al-Ayoubi, J. et al. Hepatitis E virus ORF 1 induces proliferative and functional T-cell responses in patients with ongoing and resolved hepatitis E. Liver Int. 38, 266–277 (2018).
Kemming, J. et al. Mechanisms of CD8+ T-cell failure in chronic hepatitis E virus infection. J. Hepatol. 77, 978–990 (2022). First in-depth analysis of T cell responses during chronic HEV3 infection; observation of HEV-specific CD8+ T cell responses that displayed features of exhaustion and identification of viral escape variant of a T cell epitope.
Aggarwal, R. et al. T-cell epitope mapping of ORF2 and ORF3 proteins of human hepatitis E virus. J. Viral Hepat. 14, 283–292 (2007).
TrehanPati, N. et al. Gene expression profiles of T cells from hepatitis E virus infected patients in acute and resolving phase. J. Clin. Immunol. 31, 498–508 (2011).
Dalton, H. R. et al. Autochthonous hepatitis E in southwest England. J. Viral Hepat. 14, 304–309 (2007).
Kamar, N., Dalton, H. R., Abravanel, F. & Izopet, J. Hepatitis E virus infection. Clin. Microbiol. Rev. 27, 116–138 (2014).
Manka, P. et al. Hepatitis E virus infection as a possible cause of acute liver failure in Europe. Clin. Gastroenterol. Hepatol. 13, 1836–1842.e2 (2015).
Pal, R. et al. Immunological alterations in pregnant women with acute hepatitis E. J. Gastroenterol. Hepatol. 20, 1094–1101 (2005).
Wu, J. et al. Th1/Th2 cells and associated cytokines in acute hepatitis E and related acute liver failure. J. Immunol. Res. 2020, 6027361 (2020).
Montpellier, C. et al. Hepatitis E virus lifecycle and identification of 3 forms of the ORF2 capsid protein. Gastroenterology 154, 211–223.e8 (2018).
Gumber, D. & Wang, L. D. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. eBioMedicine 77, 103941 (2022).
Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211–218 (2019).
Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270–274 (2019).
Alfei, F. et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571, 265–269 (2019).
Chen, J. et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature 567, 530–534 (2019).
Uhl, M. et al. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64, 7954–7961 (2004).
Kumar, J. et al. Deletion of Cbl-b inhibits CD8+ T-cell exhaustion and promotes CAR T-cell function. J. Immunother. Cancer 9, e001688 (2021).
Ford, B. R. et al. Tumor microenvironmental signals reshape chromatin landscapes to limit the functional potential of exhausted T cells. Sci. Immunol. 7, eabj9123 (2022).
Soon, C. F. et al. Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E. J. Hepatol. 71, 673–684 (2019). Identification of T cell receptors targeting HLA-A2 restricted HEV-specific CD8+ T cell epitopes, which can function as a redirected TCR therapy approach for patients with chronic HEV.
Soon, C. F. et al. Hepatitis E virus (HEV)-specific T cell receptor cross-recognition: implications for immunotherapy. Front. Immunol. 10, 2076 (2019).
Bertoletti, A. et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369, 407–410 (1994).
McMichael, A. T cell responses and viral escape. Cell 93, 673–676 (1998).
Thimme, R. T cell immunity to hepatitis C virus: lessons for a prophylactic vaccine. J. Hepatol. 74, 220–229 (2021).
Katayama, Y., Yokota, R., Akiyama, T. & Kobayashi, T. J. Machine learning approaches to TCR repertoire analysis. Front. Immunol. 13, 858057 (2022).
Lu, T. et al. Deep learning-based prediction of the T cell receptor–antigen binding specificity. Nat. Mach. Intell. 3, 864–875 (2021).
Shoukat, M. S. et al. Use of machine learning to identify a T cell response to SARS-CoV-2. Cell Rep. Med. 2, 100192 (2021).
Kulkarni, S. P., Sharma, M. & Tripathy, A. S. Antibody and memory B cell responses in hepatitis E recovered individuals, 1-30 years post hepatitis E virus infection. Sci. Rep. 9, 4090 (2019).
Srivastava, R. et al. Adaptive immune responses during acute uncomplicated and fulminant hepatitis E. J. Gastroenterol. Hepatol. 26, 306–311 (2011).
Sharma, M. & Tripathy, A. S. Regulatory role of B cells and its subsets in hepatitis E virus infection. BioMed. Res. Int. 2022, 7932150 (2022).
Chau, K. H. et al. Detection of IgA class antibody to hepatitis E virus in serum samples from patients with hepatitis E virus infection. J. Med. Virol. 40, 334–338 (1993).
Clayson, E. T. et al. Viremia, fecal shedding, and IgM and IgG responses in patients with hepatitis E. J. Infect. Dis. 172, 927–933 (1995).
Huang, S. et al. Profile of acute infectious markers in sporadic hepatitis E. PLoS One 5, e13560 (2010).
Bryan, J. P. et al. Epidemic hepatitis E in Pakistan: patterns of serologic response and evidence that antibody to hepatitis E virus protects against disease. J. Infect. Dis. 170, 517–521 (1994).
Chandra, N. S., Sharma, A., Malhotra, B. & Rai, R. R. Dynamics of HEV viremia, fecal shedding and its relationship with transaminases and antibody response in patients with sporadic acute hepatitis E. Virol. J. 7, 213 (2010).
Zhang, J. Z. et al. Occurrence of hepatitis E virus IgM, low avidity IgG serum antibodies, and viremia in sporadic cases of non-A, -B, and -C acute hepatitis. J. Med. Virol. 66, 40–48 (2002).
Bendall, R., Ellis, V., Ijaz, S., Thurairajah, P. & Dalton, H. R. Serological response to hepatitis E virus genotype 3 infection: IgG quantitation, avidity, and IgM response. J. Med. Virol. 80, 95–101 (2008).
Schemmerer, M., Rauh, C., Jilg, W. & Wenzel, J. J. Time course of hepatitis E-specific antibodies in adults. J. Viral Hepat. 24, 75–79 (2017).
Sultankhuroo, M. Hepatitis E and long-term antibody status. Lancet 341, 1355 (1993).
Takahashi, M. et al. Hepatitis E virus (HEV) strains in serum samples can replicate efficiently in cultured cells despite the coexistence of HEV antibodies: characterization of HEV virions in blood circulation. J. Clin. Microbiol. 48, 1112–1125 (2010).
Vollmer, T., Diekmann, J., Eberhardt, M., Knabbe, C. & Dreier, J. Hepatitis E in blood donors: investigation of the natural course of asymptomatic infection, Germany, 2011. Euro Surveill. 21, 30332 (2016).
Kraef, C. et al. Course of HEV viremia and anti-HEV IgM/IgG response in asymptomatic blood donors. J. Clin. Virol. 105, 26–30 (2018).
Legrand-Abravanel, F. et al. Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J. Infect. Dis. 202, 835–844 (2010).
Choi, M. et al. Prevalence and clinical correlates of chronic hepatitis E infection in German renal transplant recipients with elevated liver enzymes. Transplant. Direct 4, e341 (2018).
Haagsma, E. B. et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transplant. 14, 547–553 (2008).
Pas, S. D. et al. Hepatitis E virus infection among solid organ transplant recipients, the Netherlands. Emerg. Infect. Dis. 18, 869–872 (2012).
Tamura, A. et al. Persistent infection of hepatitis E virus transmitted by blood transfusion in a patient with T-cell lymphoma. Hepatol. Res. 37, 113–120 (2007).
Pischke, S. et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transplant. 16, 74–82 (2010).
Rentenaar, R. J. et al. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int. 62, 319–328 (2002).
Luo, H. et al. Inhibition of in vitro immunoglobulin production by rapamycin. Transplantation 53, 1071–1076 (1992).
Aagaard-Tillery, K. M. & Jelinek, D. F. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell. Immunol. 156, 493–507 (1994).
Gardinali, N. R. et al. Cynomolgus monkeys are successfully and persistently infected with hepatitis E virus genotype 3 (HEV-3) after long-term immunosuppressive therapy. PLoS One 12, e0174070 (2017).
Tsarev, S. A. et al. Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc. Natl Acad. Sci. USA 91, 10198–10202 (1994).
Khuroo, M. S. & Khuroo, M. S. Seroepidemiology of a second epidemic of hepatitis E in a population that had recorded first epidemic 30 years before and has been under surveillance since then. Hepatol. Int. 4, 494–499 (2010).
Servant-Delmas, A. et al. New insights into the natural history of hepatitis E virus infection through a longitudinal study of multitransfused immunocompetent patients in France. J. Viral Hepat. 23, 569–575 (2016).
Faber, M. et al. Hepatitis E virus seroprevalence, seroincidence and seroreversion in the German adult population. J. Viral Hepat. 25, 752–758 (2018).
Hogema, B. M., Molier, M., Slot, E. & Zaaijer, H. L. Past and present of hepatitis E in the Netherlands. Transfusion 54, 3092–3096 (2014).
Choi, Y., Zhang, X. & Skinner, B. Analysis of IgG anti-HEV antibody protective levels during hepatitis E virus reinfection in experimentally infected rhesus macaques. J. Infect. Dis. 219, 916–924 (2019).
Arankalle, V. A., Chadha, M. S. & Chobe, L. P. Long-term serological follow up and cross-challenge studies in rhesus monkeys experimentally infected with hepatitis E virus. J. Hepatol. 30, 199–204 (1999).
Huang, W. et al. Cross-protection of hepatitis E virus genotypes 1 and 4 in rhesus macaques. J. Med. Virol. 80, 824–832 (2008).
Arankalle, V. A., Chadha, M. S., Chobe, L. P., Nair, R. & Banerjee, K. Cross-challenge studies in rhesus monkeys employing different Indian isolates of hepatitis E virus. J. Med. Virol. 46, 358–363 (1995).
Abravanel, F. et al. Hepatitis E virus reinfections in solid-organ-transplant recipients can evolve into chronic infections. J. Infect. Dis. 209, 1900–1906 (2014).
Ferguson, M., Walker, D., Mast, E. & Fields, H. Report of a collaborative study to assess the suitability of a reference reagent for antibodies to hepatitis E virus. Biologicals 30, 43–48 (2002). The authors identified the WHO HEV IgG reference reagent 95/584 and found it to be suitable to serve as a reference reagent for hepatitis E serum IgG and established the reagent as an interim reference reagent for human anti-hepatitis E serum.
Behrendt, P. & Wedemeyer, H. Impfstoffe gegen hepatitis E: Wo stehen wir? Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 65, 192–201 (2022).
Zhang, J. et al. Long-term efficacy of a hepatitis E vaccine. N. Engl. J. Med. 372, 914–922 (2015).
Zhu, F.-C. et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 376, 895–902 (2010). First clinical trial examining a truncated ORF2 termed HEV 239 (trade name Hecolin) for the prevention and vaccination of HEV1 infection.
World Health Organization. Safety of Hepatitis E Vaccines https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/hepatitis-e-vaccines (2023).
Li, S. W. et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine 23, 2893–2901 (2005).
Ciglenecki, I. et al. The first reactive vaccination campaign against hepatitis E. Lancet Infect. Dis. 22, 1110–1111 (2022).
Nesbitt, R. C. et al. Vaccination coverage and adverse events following a reactive vaccination campaign against hepatitis E in Bentiu displaced persons camp, South Sudan. PLoS Negl. Trop. Dis. 18, e0011661 (2024).
Purcell, R. H. et al. Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine. Vaccine 21, 2607–2615 (2003).
Safary, A. Perspectives of vaccination against hepatitis E. Intervirology 44, 162–166 (2001).
Emerson, S. U. & Purcell, R. H. Recombinant vaccines for hepatitis E. Trends Mol. Med. 7, 462–466 (2001).
Shrestha, M. P. et al. Safety and efficacy of a recombinant hepatitis E vaccine. N. Engl. J. Med. 356, 895–903 (2007).
Stevenson, P. Nepal calls the shots in hepatitis E virus vaccine trial. Lancet 355, 1623 (2000).
Basu, S. & Lurie, P. Hepatitis E vaccine. N. Engl. J. Med. 356, 2421–2422 (2007).
Andrews, J. U.S. Military sponsored vaccine trials and la resistance in Nepal. Am. J. Bioeth. 5, W1–W3 (2005).
Meng, J. et al. Identification and characterization of the neutralization epitope(s) of the hepatitis E virus. Virology 288, 203–211 (2001).
Wen, J. et al. Immunogenicity difference between two hepatitis E vaccines derived from genotype 1 and 4. Antivir. Res. 128, 36–42 (2016).
Cao, Y.-F. et al. A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine. Vaccine 35, 5073–5080 (2017).
Lynch, J. A. et al. Hepatitis E vaccine — illuminating the barriers to use. PLoS Negl. Trop. Dis. 17, e0010969 (2023).
World Health Organization. Who Position Paper on Hepatitis E Vaccines — May 2015 https://www.who.int/publications/i/item/WER9018-185-200 (2015).
Reyes, G. R. et al. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 247, 1335–1339 (1990). Isolation and cloning of the cDNA HEV genome.
Tam, A. W. et al. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology 185, 120–131 (1991).
Panda, S. K., Ansari, I. H., Durgapal, H., Agrawal, S. & Jameel, S. The in vitro-synthesized RNA from a cDNA clone of hepatitis E virus is infectious. J. Virol. 74, 2430–2437 (2000).
Emerson, S. U. et al. Recombinant hepatitis E virus genomes infectious for primates: importance of capping and discovery of a cis-reactive element. Proc. Natl Acad. Sci. USA 98, 15270–15275 (2001).
Tei, S., Kitajima, N., Takahashi, K. & Mishiro, S. Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 362, 371–373 (2003). First direct evidence of zoonotic transmission of hepatitis E virus.
Baylis, S. A. et al. World Health Organization International Standard to harmonize assays for detection of hepatitis E virus RNA. Emerg. Infect. Dis. 19, 729–735 (2013).
Kamar, N. et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N. Engl. J. Med. 370, 1111–1120 (2014). Ribavirin as monotherapy for the treatment of chronic HEV infection.
Xing, L. et al. Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway. J. Biol. Chem. 285, 33175–33183 (2010). Identification of virion-sized capsids with a T = 3 icosahedral lattice structure by cryo-electron microscopy; the authors also demonstrate that RNA binding is the extrinsic factor essential for the assembly of HEV native capsids.
Ralfs, P. et al. Soluble ORF2 protein enhances HEV replication and induces long-lasting antibody response and protective immunity in vivo. Hepatology 78, 1867–1881 (2023).
Yin, X. et al. Origin, antigenicity, and function of a secreted form of ORF2 in hepatitis E virus infection. Proc. Natl Acad. Sci. USA 115, 4773–4778 (2018).
Meister, T. L. et al. A ribavirin-induced ORF2 single-nucleotide variant produces defective hepatitis E virus particles with immune decoy function. Proc. Natl Acad. Sci. USA 119, e2202653119 (2022).
Yamashita, T. et al. Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure. Proc. Natl Acad. Sci. USA 106, 12986–12991 (2009).
Guu, T. S. Y. et al. Structure of the hepatitis E virus-like particle suggests mechanisms for virus assembly and receptor binding. Proc. Natl Acad. Sci. USA 106, 12992–12997 (2009).
Schofield, D. J., Glamann, J., Emerson, S. U. & Purcell, R. H. Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein. J. Virol. 74, 5548–5555 (2000).
Zheng, Q. et al. Viral neutralization by antibody-imposed physical disruption. Proc. Natl Acad. Sci. USA 116, 26933–26940 (2019).
Li, S. et al. Dimerization of hepatitis E virus capsid protein E2s domain is essential for virus-host interaction. PLoS Pathog. 5, e1000537 (2009).
Xing, L. et al. Spatial configuration of hepatitis E virus antigenic domain. J. Virol. 85, 1117–1124 (2011).
Zhang, J. et al. Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein. Vaccine 23, 2881–2892 (2005).
Xing, L. et al. Recombinant hepatitis E capsid protein self-assembles into a dual-domain T = 1 particle presenting native virus epitopes. Virology 265, 35–45 (1999).
Li, T., Takeda, N. & Miyamura, T. Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. Vaccine 19, 3476–3484 (2001).
Li, T. C. et al. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J. Virol. 71, 7207–7213 (1997).
Shima, R. et al. Production of hepatitis E virus-like particles presenting multiple foreign epitopes by co-infection of recombinant baculoviruses. Sci. Rep. 6, 21638 (2016).
Schofield, D. J., Purcell, R. H., Nguyen, H. T. & Emerson, S. U. Monoclonal antibodies that neutralize HEV recognize an antigenic site at the carboxyterminus of an ORF2 protein vaccine. Vaccine 22, 257–267 (2003).
Li, T.-C. et al. Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus. J. Virol. 79, 12999–13006 (2005).
Purdy, M. A. et al. Preliminary evidence that a trpE-HEV fusion protein protects cynomolgus macaques against challenge with wild-type hepatitis E virus (HEV). J. Med. Virol. 41, 90–94 (1993).
Ghabrah, T. M. et al. Comparison of tests for antibody to hepatitis E virus. J. Med. Virol. 55, 134–137 (1998).
Kaur, M. et al. Human linear B-cell epitopes encoded by the hepatitis E virus include determinants in the RNA-dependent RNA polymerase. Proc. Natl Acad. Sci. USA 89, 3855–3858 (1992).
Khudyakov, Y., Favorov, M. O., Jue, D. L., Hine, T. K. & Fields, H. A. Immunodominant antigenic regions in a structural protein of the hepatitis E virus. Virology 198, 390–393 (1994).
Riddell, M. A., Li, F. & Anderson, D. A. Identification of immunodominant and conformational epitopes in the capsid protein of hepatitis E virus by using monoclonal antibodies. J. Virol. 74, 8011–8017 (2000).
Tang, X. et al. Structural basis for the neutralization and genotype specificity of hepatitis E virus. Proc. Natl Acad. Sci. USA 108, 10266–10271 (2011).
Emerson, S. U. et al. Putative neutralization epitopes and broad cross-genotype neutralization of Hepatitis E virus confirmed by a quantitative cell-culture assay. J. Gen. Virol. 87, 697–704 (2006).
Gu, Y. et al. Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody. Cell Res. 25, 604–620 (2015).
Li, S.-W. et al. Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid. J. Biol. Chem. 280, 3400–3406 (2005).
Acknowledgements
The authors thank Jörg Timm, Volker Kinast and Viet Loan Dao Thi for comments on the manuscript. Moreover, we thank all members of the Department for Molecular and Medical Virology, Ruhr University Bochum, for helpful support, suggestions and discussions. E.S. was supported by grants from the German Research Foundation (DFG, grant number: 510558817) and the medical faculty of the Ruhr University Bochum (InnovationsFoRUM, grant number: IF-018N-22). H.W. and E.S. were funded by a grant from the German Centre for Infection Research (DZIF). Y.B. was supported by the medical faculty of the Ruhr University Bochum (FoRUM, grant number: F1030-2021).
Author information
Authors and Affiliations
Contributions
Y.B., M.K., H.W. and E.S. developed the concept and coordinated the manuscript. Y.B. and M.K. wrote the manuscript and generated the original version of the figures. All authors reviewed the final manuscript.
Corresponding author
Ethics declarations
Competing interests
H.W. consults for, is on the speakers’ bureau for, received grants from, and has other interests in Gilead Sciences, Inc. He consults for, received grants from, and has other interests in Falk. He consults for and has other interests in Merck Sharp & Dohme. He consults for and advises Roche. He consults for and is on the speakers’ bureau for Pfizer Inc. He is on the speakers’ bureau for the Falk Foundation. The other authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Gastroenterology & Hepatology thanks Jacques Izopet; Alexander Ploss; and Jun Zhang, who co-reviewed with Zizheng Zheng, for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Brüggemann, Y., Klöhn, M., Wedemeyer, H. et al. Hepatitis E virus: from innate sensing to adaptive immune responses. Nat Rev Gastroenterol Hepatol 21, 710–725 (2024). https://doi.org/10.1038/s41575-024-00950-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-024-00950-z